Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C. uri icon

Overview

abstract

  • BACKGROUND: Mycobacterium avium-intracellulare (MAI) is a well-described pathogen in patients with acquired immune deficiency syndrome (AIDS). However, peritonitis and severe sepsis as a complication of disseminated MAI is rare. We report a case that represents the first successful use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis secondary to mycobacterial infection and only the second reported case of MAI peritonitis with no known predisposing factor other than AIDS. METHODS: Case report and review of the pertinent literature. RESULTS: A 36-year-old man with AIDS presented to the emergency department with acute-onset right-sided abdominal pain, fever, and chills. Abdominal computed tomography revealed multiple rim-enhancing fluid collections. Despite immediate surgical drainage and debridement and appropriate antimicrobial therapy targeting the non-tuberculous acid-fast bacilli found in intraperitoneal fluid, the patient developed severe sepsis and septic shock. Clinical improvement occurred after infusion of recombinant human activated protein C (rhAPC) and specific antimicrobial chemotherapy directed against MAI. CONCLUSIONS: Treatment with rhAPC decreases the mortality rate of bacterial sepsis of abdominal origin and may confer a similar benefit in the treatment of abdominal mycobacterial sepsis.

publication date

  • June 1, 2008

Research

keywords

  • Anti-Infective Agents
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection
  • Peritonitis
  • Protein C
  • Sepsis

Identity

Scopus Document Identifier

  • 45749127396

Digital Object Identifier (DOI)

  • 10.1089/sur.2007.050

PubMed ID

  • 18570580

Additional Document Info

volume

  • 9

issue

  • 3